Solara Active Pharma Sciences Ltd.
Snapshot View

View in App

Prices View details

430.40 +1.70 ▲0.4%

20 May 2022, 04:01:00 PM
Volume: 11,991

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.solara.co.in
Market Cap 1,549.28 Cr.
Enterprise Value(EV) 2,526.60 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) -16.15 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-03
Industry PE 29.26 Trailing Twelve Months Ending 2022-03
Book Value / Share 423.63 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.02 Calculated using Price: 430.40
Dividend Yield 1.63 Period Ending 2021-03
No. of Shares Subscribed 3.60 Cr. 35,996,267 Shares
FaceValue 10
Company Profile
Solara Active Pharma Sciences is a dynamic, entrepreneurial and customer-oriented API manufacturer. It has a legacy of over three decades and trace its origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd.

The company is poised to bridge the industry gap by delivering value-based products while maintaining focus on customer needs. It has hundreds of scientists working at its two R&D Centers and many API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities. 

The company has a highly compliant manufacturing footprint spread over six large scale multi-product facilities. The company’s business is spread across several countries with extensive operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. 

Business area of the company

The company is a global, R&D focused, pureplay API company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies. 

Products and services
  • Commercial and R&D products
  • Contract research and Manufacturing

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.40%
1 Week
-3.32%
1 Month
-39.15%
3 Month
-44.04%
6 Month
-58.74%
1 Year
-75.41%
2 Year
-6.80%
5 Year
10 Year

Ratios View Details

4 years 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 0.04 7.36 12.48 17.23
Return on Capital Employed (%) 1.82 9.70 11.73 15.34
Return on Assets (%) 0.02 3.14 5.57 9.34

Balance Sheet View Details

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 764 956 1,086 1,589 1,525
Non Curr. Liab. 315 344 333 206 299
Curr. Liab. 738 656 730 789 1,071
Minority Int. 4 4 4 4 2
Equity & Liab. 1,821 1,960 2,153 2,588 2,897
Non Curr. Assets 1,214 1,312 1,481 1,530 1,658
Curr. Assets 608 648 672 1,058 1,239
Misc. Exp. not W/O
Total Assets 1,821 1,960 2,153 2,588 2,897

Profit Loss View Details

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 560 1,409 1,322 1,617 1,268
Other Income 2 12 28 29 20
Total Income 563 1,421 1,349 1,646 1,288
Total Expenditure -501 -1,197 -1,062 -1,231 -1,188
PBIDT 62 224 287 415 100
Interest -25 -82 -78 -84 -75
Depreciation -37 -84 -94 -109 -112
Taxation 0 2 0 0 33
Exceptional Items -3
PAT 0 59 115 221 -58
Minority Interest 0 0 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 0 60 115 221 -58
Adjusted EPS 0 23 43 62 -16

Cash Flow View Details

Particulars 4 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 49 166 242 155
Cash Fr. Inv. -85 -116 -359 -106
Cash Fr. Finan. 68 -23 97 92
Net Change 31 27 -20 142
Cash & Cash Eqvt 46 76 56 198

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 41.88 41.88 44.24 44.13 44.11 41.07 41.07 39.51 39.71
Public 58.12 58.12 55.76 55.87 55.89 58.93 58.93 60.49 60.29
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 51.12 0.00 17.09 16.42 8.86 13.55 29.44 27.51

Announcements View Details

Sat, 21 May 2022
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Karuna Business Solutions LLP
Fri, 13 May 2022
Disclosure Of Related Party Transactions For The Period Ended March 31 2022
Disclosure Of Related Party Transactions For The period Ended March 31 2022
Fri, 13 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company Solara Active Pharma Sciences Ltd
2 CIN NO. L24230MH2017PLC291636
3 Report filed for FY 2021-2022
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* 2021-22 2022-23
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)2020-21 2021-22
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-S Murali Krishna
Designation :-Company Secretary
Name of the Chief Financial Officer :- S Hariiharan
Designation : -ED and CFO

Date: 13/05/2022

Technical Scans View Details

Fri, 20 May 2022
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Decrease 6 Months High Decrease 6 Months
High Decrease 1 Year High Decrease 1 Year

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%